OncoMatch/Clinical Trials/NCT07641049
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Is NCT07641049 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including ETB-DualNK-01 and Fludarabine for metastatic castration-resistant prostate cancer.
Treatment: ETB-DualNK-01 · Fludarabine · Cyclophosphamide — This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: PSMA expression (testing required; no eligibility threshold specified)
Documented PSMA and/or PSCA expression by a validated tumor assay; PSMA PET may support target confirmation when applicable
Required: PSCA expression (testing required; no eligibility threshold specified)
Documented PSMA and/or PSCA expression by a validated tumor assay
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide)
Prior progression on at least one androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide
Cannot have received: allogeneic transplant requiring ongoing systemic immunosuppression
prior allogeneic transplant requiring ongoing systemic immunosuppression
Lab requirements
Blood counts
adequate hematologic function per protocol laboratory thresholds
Kidney function
adequate renal function per protocol laboratory thresholds
Liver function
adequate hepatic function per protocol laboratory thresholds
Cardiac function
adequate cardiac function per protocol laboratory thresholds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07641049 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic transplant requiring ongoing systemic immunosuppression disqualifies patients from enrollment.
Does this trial require PSMA?
Yes, PSMA expression is a required biomarker for enrollment.
Does this trial require PSCA?
Yes, PSCA expression is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages